Bio­Marin scales back launch for he­mo­phil­ia gene ther­a­py, pitch­es path to prof­itabil­i­ty

Bio­Marin Phar­ma­ceu­ti­cal is reel­ing in its gene ther­a­py am­bi­tions. On Mon­day, the com­pa­ny an­nounced that it’s low­er­ing spend­ing plans for its he­mo­phil­ia gene ther­a­py, Roc­ta­vian …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER